Stock Taper
| DATE | TYPE | RATIO |
|---|---|---|
| 2024-07-18 | Reverse | 1:10 |
Senti Biosciences develops gene circuit-based cell therapies, including off-the-shelf CAR-NK treatments targeting cancers like AML, HCC, and CRC through engineered biological logic to precisely reprogram immune responses.

SENTI-202 is a clinical-stage off-the-shelf CAR-NK therapy targeting CD33 and FLT3 for AML and blood cancers, recently completed Phase 1 enrollment and received FDA RMAT designation.
| Icon | PRODUCT | Q1-2023 | Q2-2023 | Q2-2026 |
|---|---|---|---|---|
![]() | License | $400K | $200K ▼ | — |
![]() | Reportable Segment | — | — | $17K |
Overall rating: C
| PEER | PRICE | |
|---|---|---|
XFOR | $4.04 | COMPARE |
IPSC | $2.02 | COMPARE |
CUE | $27.88 | COMPARE |
ALGS | $6.91 | COMPARE |
KPTI | $1.87 | COMPARE |
BRNS | $0.75 | COMPARE |
GNTA | $1.00 | COMPARE |
MDCX | $0.26 | COMPARE |